| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.
|
JAMA
|
2002
|
80.37
|
|
2
|
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.
|
JAMA
|
2004
|
23.69
|
|
3
|
Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group.
|
Control Clin Trials
|
1998
|
20.39
|
|
4
|
Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial.
|
JAMA
|
2006
|
12.44
|
|
5
|
Calcium plus vitamin D supplementation and the risk of fractures.
|
N Engl J Med
|
2006
|
12.09
|
|
6
|
Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.
|
JAMA
|
2003
|
11.39
|
|
7
|
Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial.
|
JAMA
|
2003
|
10.61
|
|
8
|
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.
|
JAMA
|
2007
|
10.50
|
|
9
|
Measurement characteristics of the Women's Health Initiative food frequency questionnaire.
|
Ann Epidemiol
|
1999
|
10.36
|
|
10
|
Calcium plus vitamin D supplementation and the risk of colorectal cancer.
|
N Engl J Med
|
2006
|
8.73
|
|
11
|
Estrogen therapy and coronary-artery calcification.
|
N Engl J Med
|
2007
|
8.70
|
|
12
|
Outcomes ascertainment and adjudication methods in the Women's Health Initiative.
|
Ann Epidemiol
|
2003
|
8.64
|
|
13
|
Walking compared with vigorous exercise for the prevention of cardiovascular events in women.
|
N Engl J Med
|
2002
|
7.77
|
|
14
|
Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.
|
JAMA
|
2013
|
7.19
|
|
15
|
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women.
|
JAMA
|
2010
|
7.12
|
|
16
|
Frailty: emergence and consequences in women aged 65 and older in the Women's Health Initiative Observational Study.
|
J Am Geriatr Soc
|
2005
|
6.73
|
|
17
|
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial.
|
JAMA
|
2006
|
6.51
|
|
18
|
Low-fat dietary pattern and weight change over 7 years: the Women's Health Initiative Dietary Modification Trial.
|
JAMA
|
2006
|
5.75
|
|
19
|
Pelvic organ prolapse in the Women's Health Initiative: gravity and gravidity.
|
Am J Obstet Gynecol
|
2002
|
5.73
|
|
20
|
Estrogen plus progestin and colorectal cancer in postmenopausal women.
|
N Engl J Med
|
2004
|
5.65
|
|
21
|
Effects of estrogen with and without progestin on urinary incontinence.
|
JAMA
|
2005
|
5.41
|
|
22
|
Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.
|
JAMA
|
2004
|
5.35
|
|
23
|
Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial.
|
JAMA
|
2003
|
5.26
|
|
24
|
Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial.
|
Lancet
|
2009
|
5.22
|
|
25
|
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis.
|
Lancet
|
2012
|
4.87
|
|
26
|
Effects of estrogen plus progestin on health-related quality of life.
|
N Engl J Med
|
2003
|
4.83
|
|
27
|
Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial.
|
Am J Epidemiol
|
2005
|
4.55
|
|
28
|
Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin.
|
JAMA
|
2008
|
4.42
|
|
29
|
Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial.
|
Ann Intern Med
|
2010
|
4.27
|
|
30
|
Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women's Health Initiative Observational Study.
|
Arch Intern Med
|
2005
|
4.24
|
|
31
|
Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial.
|
JAMA
|
2003
|
4.07
|
|
32
|
Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.
|
JAMA
|
2003
|
4.03
|
|
33
|
Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study.
|
JAMA
|
2004
|
3.85
|
|
34
|
Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial.
|
JAMA
|
2011
|
3.85
|
|
35
|
Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk: A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trials.
|
JAMA Oncol
|
2015
|
3.64
|
|
36
|
Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial.
|
Lancet Oncol
|
2012
|
3.56
|
|
37
|
Comparison of self-report, hospital discharge codes, and adjudication of cardiovascular events in the Women's Health Initiative.
|
Am J Epidemiol
|
2004
|
3.53
|
|
38
|
Estrogen plus progestin and risk of venous thrombosis.
|
JAMA
|
2004
|
3.46
|
|
39
|
Validity of self-report for fractures among a multiethnic cohort of postmenopausal women: results from the Women's Health Initiative observational study and clinical trials.
|
Menopause
|
2004
|
3.33
|
|
40
|
Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy.
|
JAMA
|
2006
|
3.29
|
|
41
|
Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States).
|
Cancer Causes Control
|
2002
|
3.27
|
|
42
|
Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study.
|
JAMA
|
2002
|
3.01
|
|
43
|
Sexual orientation and health: comparisons in the women's health initiative sample.
|
Arch Fam Med
|
2000
|
2.97
|
|
44
|
Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial.
|
JAMA
|
2006
|
2.97
|
|
45
|
Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial.
|
JAMA
|
2003
|
2.90
|
|
46
|
Association between cardiovascular outcomes and antihypertensive drug treatment in older women.
|
JAMA
|
2004
|
2.90
|
|
47
|
Postmenopausal hormone use and the risk of nephrolithiasis: results from the Women's Health Initiative hormone therapy trials.
|
Arch Intern Med
|
2010
|
2.89
|
|
48
|
Calcium plus vitamin D supplementation and the risk of incident diabetes in the Women's Health Initiative.
|
Diabetes Care
|
2008
|
2.76
|
|
49
|
The Women's Health Initiative Dietary Modification trial: overview and baseline characteristics of participants.
|
Ann Epidemiol
|
2003
|
2.64
|
|
50
|
Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial.
|
Diabetologia
|
2004
|
2.63
|
|
51
|
Multivitamin use and risk of cancer and cardiovascular disease in the Women's Health Initiative cohorts.
|
Arch Intern Med
|
2009
|
2.54
|
|
52
|
Menopausal symptom experience before and after stopping estrogen therapy in the Women's Health Initiative randomized, placebo-controlled trial.
|
Menopause
|
2010
|
2.50
|
|
53
|
Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative.
|
Cancer Res
|
2003
|
2.49
|
|
54
|
Risk of cardiovascular disease by hysterectomy status, with and without oophorectomy: the Women's Health Initiative Observational Study.
|
Circulation
|
2005
|
2.49
|
|
55
|
Postmenopausal hormone therapy and regional brain volumes: the WHIMS-MRI Study.
|
Neurology
|
2009
|
2.45
|
|
56
|
Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women's Health Initiative (WHI) limited-access data set.
|
Am J Clin Nutr
|
2011
|
2.44
|
|
57
|
Low-fat dietary pattern and change in body-composition traits in the Women's Health Initiative Dietary Modification Trial.
|
Am J Clin Nutr
|
2010
|
2.43
|
|
58
|
The importance of health insurance as a determinant of cancer screening: evidence from the Women's Health Initiative.
|
Prev Med
|
2000
|
2.40
|
|
59
|
Low-fat dietary pattern and cancer incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial.
|
J Natl Cancer Inst
|
2007
|
2.37
|
|
60
|
Symptom experience after discontinuing use of estrogen plus progestin.
|
JAMA
|
2005
|
2.32
|
|
61
|
Urinary tract stone occurrence in the Women's Health Initiative (WHI) randomized clinical trial of calcium and vitamin D supplements.
|
Am J Clin Nutr
|
2011
|
2.21
|
|
62
|
Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: results from the Women's Health Initiative Randomized Clinical Trial.
|
Arch Intern Med
|
2005
|
2.17
|
|
63
|
Aspirin is associated with lower melanoma risk among postmenopausal Caucasian women: the Women's Health Initiative.
|
Cancer
|
2013
|
2.14
|
|
64
|
Rheumatoid Arthritis, Anti-Cyclic Citrullinated Peptide Positivity, and Cardiovascular Disease Risk in the Women's Health Initiative.
|
Arthritis Rheumatol
|
2015
|
2.07
|
|
65
|
Evaluation and comparison of food records, recalls, and frequencies for energy and protein assessment by using recovery biomarkers.
|
Am J Epidemiol
|
2011
|
2.04
|
|
66
|
Calcium plus vitamin D supplementation and mortality in postmenopausal women: the Women's Health Initiative calcium-vitamin D randomized controlled trial.
|
J Gerontol A Biol Sci Med Sci
|
2009
|
2.01
|
|
67
|
Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative.
|
Obstet Gynecol
|
2005
|
2.01
|
|
68
|
Calcium/vitamin D supplementation and coronary artery calcification in the Women's Health Initiative.
|
Menopause
|
2010
|
2.00
|
|
69
|
Resting heart rate as a low tech predictor of coronary events in women: prospective cohort study.
|
BMJ
|
2009
|
1.99
|
|
70
|
Biomarker-calibrated energy and protein consumption and increased cancer risk among postmenopausal women.
|
Am J Epidemiol
|
2009
|
1.98
|
|
71
|
Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy.
|
Arch Intern Med
|
2008
|
1.94
|
|
72
|
Low-fat dietary pattern and risk of treated diabetes mellitus in postmenopausal women: the Women's Health Initiative randomized controlled dietary modification trial.
|
Arch Intern Med
|
2008
|
1.89
|
|
73
|
Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study.
|
Arch Intern Med
|
2005
|
1.85
|
|
74
|
Association between reported alcohol intake and cognition: results from the Women's Health Initiative Memory Study.
|
Am J Epidemiol
|
2005
|
1.83
|
|
75
|
Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study.
|
Ann Intern Med
|
2003
|
1.81
|
|
76
|
Effects of postmenopausal hormone therapy on rheumatoid arthritis: the women's health initiative randomized controlled trials.
|
Arthritis Rheum
|
2008
|
1.80
|
|
77
|
Hypertension and its treatment in postmenopausal women: baseline data from the Women's Health Initiative.
|
Hypertension
|
2000
|
1.77
|
|
78
|
Reanalysis of the Women's Health Initiative oral contraceptive data reveals no evidence of delayed cardiovascular benefit.
|
Fertil Steril
|
2005
|
1.72
|
|
79
|
The WHI estrogen-alone trial--do things look any better?
|
JAMA
|
2004
|
1.64
|
|
80
|
Magnesium intake, bone mineral density, and fractures: results from the Women's Health Initiative Observational Study.
|
Am J Clin Nutr
|
2014
|
1.60
|
|
81
|
Genetic variants in the MRPS30 region and postmenopausal breast cancer risk.
|
Genome Med
|
2011
|
1.55
|
|
82
|
Can biomarkers identify women at increased stroke risk? The Women's Health Initiative Hormone Trials.
|
PLoS Clin Trials
|
2007
|
1.54
|
|
83
|
Coronary artery calcification in black women and white women.
|
Am Heart J
|
2003
|
1.52
|
|
84
|
Baseline age and time to major fracture in younger postmenopausal women.
|
Menopause
|
2015
|
1.49
|
|
85
|
Diet quality and the risk of cardiovascular disease: the Women's Health Initiative (WHI).
|
Am J Clin Nutr
|
2011
|
1.48
|
|
86
|
Major and minor ECG abnormalities in asymptomatic women and risk of cardiovascular events and mortality.
|
JAMA
|
2007
|
1.47
|
|
87
|
Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer.
|
Cancer Epidemiol Biomarkers Prev
|
2009
|
1.46
|
|
88
|
The effect of hormone therapy on mean blood pressure and visit-to-visit blood pressure variability in postmenopausal women: results from the Women's Health Initiative randomized controlled trials.
|
J Hypertens
|
2014
|
1.45
|
|
89
|
Special populations recruitment for the Women's Health Initiative: successes and limitations.
|
Control Clin Trials
|
2004
|
1.43
|
|
90
|
Use of Medicare data to identify coronary heart disease outcomes in the Women's Health Initiative.
|
Circ Cardiovasc Qual Outcomes
|
2014
|
1.41
|
|
91
|
Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials.
|
JAMA
|
2017
|
1.40
|
|
92
|
Bone mineral density of American Indian and Alaska Native women compared with non-Hispanic white women: results from the Women's Health Initiative Study.
|
Menopause
|
2005
|
1.40
|
|
93
|
Biomarker-calibrated energy and protein consumption and cardiovascular disease risk among postmenopausal women.
|
Epidemiology
|
2011
|
1.37
|
|
94
|
Physical activity and diabetes risk in postmenopausal women.
|
Am J Prev Med
|
2005
|
1.36
|
|
95
|
Effect of estrogen therapy on gallbladder disease.
|
JAMA
|
2005
|
1.36
|
|
96
|
Recruitment of Hispanic women to the Women's Health Initiative. the case of Embajadoras in Arizona.
|
Control Clin Trials
|
2002
|
1.35
|
|
97
|
Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the women's health initiative trials of hormone therapy.
|
Arch Intern Med
|
2008
|
1.34
|
|
98
|
Postmenopausal hormone therapy and subclinical cerebrovascular disease: the WHIMS-MRI Study.
|
Neurology
|
2009
|
1.32
|
|
99
|
Biomarker-calibrated dietary energy and protein intake associations with diabetes risk among postmenopausal women from the Women's Health Initiative.
|
Am J Clin Nutr
|
2011
|
1.31
|
|
100
|
Colorectal cancer in relation to postmenopausal estrogen and estrogen plus progestin in the Women's Health Initiative clinical trial and observational study.
|
Cancer Epidemiol Biomarkers Prev
|
2009
|
1.29
|